Clopidogrel pathway

[1] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436

[2] Caplain H, 1999, SEMIN THROMB HEMOST, V25, P25

[3] The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 53 - 59

[4] Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J]. LANCET, 2009, 373 (9660) : 309 - 317

[5] Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) : 1149 - 1153

[6] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 735 - 741

[7] Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness [J]. THROMBOSIS RESEARCH, 2008, 121 (04) : 463 - 468

[8] CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [J]. PHARMACOGENOMICS, 2008, 9 (09) : 1251 - 1259

[9] Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (03) : 256 - 260

[10] Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients [J]. PHARMACOGENETICS AND GENOMICS, 2007, 17 (12) : 1057 - 1064

[1] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436

[2] Caplain H, 1999, SEMIN THROMB HEMOST, V25, P25

[3] The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 53 - 59

[4] Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J]. LANCET, 2009, 373 (9660) : 309 - 317

[5] Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) : 1149 - 1153

[6] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 735 - 741

[7] Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness [J]. THROMBOSIS RESEARCH, 2008, 121 (04) : 463 - 468

[8] CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [J]. PHARMACOGENOMICS, 2008, 9 (09) : 1251 - 1259

[9] Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (03) : 256 - 260

[10] Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients [J]. PHARMACOGENETICS AND GENOMICS, 2007, 17 (12) : 1057 - 1064